Skip to main content
Financial News
Investor Center Home
Investor Center Home
Company News
Financial News
Events & Presentations
Events Calendar
Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
Analyst Coverage
Financials
Annual Reports
SEC Filings
Governance
Governance Documents
Corporate Responsibility
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2020
2019
2018
2017
2016
2015
2014
2013
11/11/2020
Catalent, Inc. to Present at November 2020 Virtual Investor Conferences
11/03/2020
Catalent, Inc. Reports First Quarter Fiscal 2021 Results
10/16/2020
Catalent, Inc. Announces First Quarter Fiscal Year 2021 Earnings Conference Webcast
09/03/2020
Catalent, Inc. to Present at September 2020 Virtual Investor Conferences
08/31/2020
Catalent, Inc. Reports Fourth Quarter Fiscal 2020 Results
08/24/2020
Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222
07/30/2020
Catalent, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Fiscal Year 2020 Net Revenue, Earnings Before Income Taxes, and Adjusted EBITDA Significantly Ahead of Its Previous Guidance
06/25/2020
Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
06/15/2020
Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate
06/11/2020
Catalent, Inc. Announces Pricing of Public Offering of Common Stock
06/10/2020
Catalent, Inc. Announces Public Offering of Common Stock
05/28/2020
Catalent, Inc. to Present at June 2020 Virtual Investor Conferences
05/08/2020
Catalent, Inc. to Present at May 2020 Virtual Investor Conferences
05/05/2020
Catalent, Inc. Reports Third Quarter Fiscal 2020 Results
05/04/2020
Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine
04/30/2020
Catalent Announces Next Generation of Cell & Gene Therapy Leadership
04/29/2020
Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate
04/15/2020
Catalent, Inc. Announces Third Quarter Fiscal Year 2020 Earnings Conference Webcast
04/13/2020
Catalent Publishes Fiscal 2019 Corporate Responsibility Report
03/09/2020
Catalent, Inc. to Present at the Barclays Global Healthcare Conference
02/20/2020
Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2028
02/19/2020
Catalent Announces Launch of Private Offering of €450 Million of Senior Unsecured Notes Due 2028
02/18/2020
Catalent, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference
02/10/2020
Catalent Completes Acquisition of MaSTherCell
02/03/2020
Catalent, Inc. Announces Pricing of Public Offering of Common Stock
02/03/2020
Catalent, Inc. Announces Public Offering of Common Stock
02/03/2020
Catalent, Inc. Reports Second Quarter Fiscal 2020 Results
02/03/2020
Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global for $315 Million, Creating an Industry-Leading Cell & Gene Therapy Platform
01/16/2020
Catalent Further Strengthens Biologics Business with Key Senior Appointments
01/15/2020
Catalent, Inc. Announces Second Quarter Fiscal Year 2020 Earnings Conference Webcast
01/07/2020
Catalent, Inc. to Present at the 38th Annual J.P. Morgan Health Care Conference